Skip to main content
SpringerLink
Log in

HOMA-IR as a predictor of Health Outcomes in Patients with Metabolic Risk Factors: A Systematic Review and Meta-analysis

  • Review article
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

Abstract

Introduction

There exists clinical interest in the following question: Is there an association between HOMA-IR and the risk of developing metabolic diseases?

Aims

Assessing the association between high values of HOMA-IR with the incidence of T2DM, MACE, essential hypertension, dyslipidemia, NASH, and cancer in healthy participants and participants with a component of metabolic syndrome.

Methods

Databases were searched by an experienced librarian to find eligible studies. Observational cohort studies enrolling healthy adults and adults with metabolic syndrome components that evaluated HOMA as a marker of IR were considered for inclusion. Eligibility assessment, data extraction and risk of bias assessment were performed independently and in duplicate. Baseline characteristics of patients, cutoff values of HOMA-IR to predict metabolic events were extracted independently and in duplicate.

Results

38 studies (215,878 participants) proved eligible. A higher HOMA-IR value had a significant effect on the risk of developing T2DM (HR 1.87; CI 1.40–2.49), presenting non-fatal MACE (HR 1.46; CI 1.08–1.97) and hypertension (HR 1.35; CI 1.15–1.59). No association was found regarding cancer mortality and fatal MACE with higher HOMA-IR values, there was not enough information to carry out a meta-analysis to establish an association between higher values of HOMA with cancer incidence, dyslipidemia, and NASH.

Conclusions

High values of HOMA were associated with an increased risk of diabetes, hypertension, and non-fatal MACE; yet, not for cardiovascular or cancer mortality. More research is needed to determine the value of the HOMA index in metabolic and cardiovascular outcomes.

PROSPERO Registration Number

CRD42020187645.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10(1):14790.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995;75(3):473–86.

    Article  PubMed  CAS  Google Scholar 

  3. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005;26(2):19–39.

    PubMed  PubMed Central  Google Scholar 

  4. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–70.

    Article  PubMed  CAS  Google Scholar 

  5. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.

    Article  PubMed  CAS  Google Scholar 

  6. Otten J, Ahrén B, Olsson T. Surrogate measures of insulin sensitivity vs the hyperinsulinaemic–euglycaemic clamp: a meta-analysis. Diabetologia. 2014;57(9):1781–8.

    Article  PubMed  CAS  Google Scholar 

  7. Gutierrez-Buey G, Núñez-Córdoba JM, Llavero-Valero M, Gargallo J, Salvador J, Escalada J. Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes? Eur J Intern Med. 2017;41:74–8.

    Article  PubMed  CAS  Google Scholar 

  8. Baek JH, Kim H, Kim KY, Jung J. Insulin resistance and the risk of diabetes and dysglycemia in Korean General Adult Population. Diabetes Metab J. 2018;42(4):296–307.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002;25(7):1135–41.

    Article  PubMed  Google Scholar 

  10. Kurl S, Zaccardi F, Onaemo VN, Jae SY, Kauhanen J, Ronkainen K, et al. Association between HOMA-IR, fasting insulin and fasting glucose with coronary heart disease mortality in nondiabetic men: a 20-year observational study. Acta Diabetol. 2015;52(1):183–6.

    Article  PubMed  CAS  Google Scholar 

  11. Boyko EJ, Shaw JE, Zimmet PZ, Chitson P, Tuomilehto J, Alberti KGMM. A prospective study of glycemia, body size, insulin resistance and the risk of hypertension in Mauritius. J Hypertens. 2008;26(9):1742–9.

    Article  PubMed  CAS  Google Scholar 

  12. Robins SJ, Lyass A, Zachariah JP, Massaro JM, Vasan RS. Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the framingham heart study. Arterioscler Thromb Vasc Biol. 2011;31(5):1208–14.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Gast KB, Tjeerdema N, Stijnen T, Smit JWA, Dekkers OM. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS ONE. 2012;7(12): e52036.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Tohidi M, Baghbani-Oskouei A, Ahanchi NS, Azizi F, Hadaegh F. Fasting plasma glucose is a stronger predictor of diabetes than triglyceride-glucose index, triglycerides/high-density lipoprotein cholesterol, and homeostasis model assessment of insulin resistance: Tehran Lipid and Glucose Study. Acta Diabetol. 2018;55(10):1067–74.

    Article  PubMed  CAS  Google Scholar 

  15. Han SJ, Boyko EJ, Kim SK, Fujimoto WY, Kahn SE, Leonetti DL. Association of thigh muscle mass with insulin resistance and incident type 2 diabetes mellitus in Japanese Americans. Diabetes Metab J. 2018;42(6):488–95.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Wargny M, Smati S, Pichelin M, Bigot-Corbel E, Authier C, Dierry V, et al. Fatty liver index is a strong predictor of changes in glycemic status in people with prediabetes: the IT-DIAB study. PLoS ONE. 2019;14(8):e0221524.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Arellano-Campos O, Gómez-Velasco DV, Bello-Chavolla OY, Cruz-Bautista I, Melgarejo-Hernandez MA, Muñoz-Hernandez L, et al. Development and validation of a predictive model for incident type 2 diabetes in middle-aged Mexican adults: the metabolic syndrome cohort. BMC Endocr Disord. 2019;19(1):41.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Cederholm J, Zethelius B. SPISE and other fasting indexes of insulin resistance: risks of coronary heart disease or type 2 diabetes. Comparative cross-sectional and longitudinal aspects. Ups J Med Sci. 2019;124(4):265–72.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Lee S, Lacy ME, Jankowich M, Correa A, Wu WC. Association between obesity phenotypes of insulin resistance and risk of type 2 diabetes in African Americans: the Jackson Heart Study. J Clin Transl Endocrinol. 2019;19:1002210.

    Google Scholar 

  20. Maliszewska K, Adamska-Patruno E, Goscik J, Lipinska D, Citko A, Krahel A, et al. The role of muscle decline in type 2 diabetes development: a 5-year prospective observational cohort study. Nutrients. 2019;11(4):834.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Lee SH, Kwon HS, Park YM, Ha HS, Jeong SH, Yang HK, et al. Predicting the development of diabetes using the product of triglycerides and glucose: the Chungju Metabolic Disease Cohort (CMC) study. PLoS ONE. 2014;9(2):e90430.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Morimoto A, Tatsumi Y, Deura K, Mizuno S, Ohno Y, Miyamatsu N, et al. Impact of impaired insulin secretion and insulin resistance on the incidence of type 2 diabetes mellitus in a Japanese population: the Saku study. Diabetologia. 2013;56(8):1671–9.

    Article  PubMed  CAS  Google Scholar 

  23. Ruijgrok C, Dekker JM, Beulens JW, Brouwer IA, Coupé VMH, Heymans MW, et al. Size and shape of the associations of glucose, HbA1c, insulin and HOMA-IR with incident type 2 diabetes: the Hoorn Study. Diabetologia. 2018;61(1):93–100.

    Article  PubMed  CAS  Google Scholar 

  24. Ghasemi A, Tohidi M, Derakhshan A, Hasheminia M, Azizi F, Hadaegh F. Cut-off points of homeostasis model assessment of insulin resistance, beta-cell function, and fasting serum insulin to identify future type 2 diabetes: Tehran Lipid and Glucose Study. Acta Diabetol. 2015;52(5):905–15.

    Article  PubMed  CAS  Google Scholar 

  25. Derakhshan A, Tohidi M, Arshi B, Khalili D, Azizi F, Hadaegh F. Relationship of hyperinsulinaemia, insulin resistance and B-cell dysfunction with incident diabetes and pre-diabetes: the Theran Lipid and Glucose Study. Diabet Med. 2015;32(1):24–32.

    Article  PubMed  CAS  Google Scholar 

  26. Zethelius B, Cederholm J. Comparison between indexes of insulin resistance for risk prediction of cardiovascular diseases or development of diabetes. Diabetes Res Clin Pract. 2015;110(2):183–92.

    Article  PubMed  CAS  Google Scholar 

  27. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, et al. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes. 2004;53(7):1782–9.

    Article  PubMed  CAS  Google Scholar 

  28. Flores-Guerrero JL, Connelly MA, Shalaurova I, Gruppen EG, Kieneker LM, Dullaart RPF, et al. Lipoprotein insulin resistance index, a high-throughput measure of insulin resistance, is associated with incident type II diabetes mellitus in the Prevention of Renal and Vascular End-Stage Disease study. J Clin Lipidol. 2019;13(1):129–37.

    Article  PubMed  Google Scholar 

  29. Venkataraman K, Khoo CM, Leow MK, Khoo EY, Issac AV, Zagorodnov, et al. New measure of insulin sensitivity predicts cardiovascular disease better than HOMA estimated insulin resistance. PLoS One. 2013;8(9):e74410.

  30. Kim CH, Kim HK, Kim EH, Bae SJ, Park JY. Relative contributions of insulin resistance and B-cell dysfunction to the development of Type 2 diabetes in Koreans. Diabet Med. 2013;30(9):1075–9.

    Article  PubMed  CAS  Google Scholar 

  31. Wang T, Lu J, Shi L, Chen G, Xu M, Xu Y, et al. Cardiometabolic Disease and Cancer Cohort Study Group. Association of insulin resistance and B-cell dysfunction with incident diabetes among adults in Chine: a nationwide, population-based, prospective cohort study. Lancet Diabetes Endocrinol. 2020;8(2):115–124.

  32. Lee CH, Shih AZ, Woo YC, Fong CH, Leung OY, Janus E, et al. Optimal cut-offs of homeostasis model assessment of insulin resistance (HOMA-IR) to identify dysglycemia and type 2 diabetes mellitus: a 15-year prospective study in Chinese. PLoS ONE. 2016;11(9):e0163424.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Sorrentino P, Terracciano L, D’Angelo S, Ferbo U, Bracigliano A, Vecchione R. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am J Gastroenterol. 2010;105(2):336–44.

    Article  PubMed  CAS  Google Scholar 

  34. Arshi B, Tohidi M, Derakhshan A, Asgari S, Azizi F, Hadaegh F. Sex-specific relations between fasting insulin, insulin resitance and incident hypertension: 89 years follow-up in a Middel-Eastern population. J Hum Hypertens. 2015;29(4):260–7.

    Article  PubMed  CAS  Google Scholar 

  35. Bruno G, Fornengo P, Segre O, Novelli G, Panero F, Perotto M, et al. What is the clinical usefulness of the metabolic syndrome? The Casale Monferrato study. J Hypertens. 2009;27(12):2403–8.

    Article  PubMed  CAS  Google Scholar 

  36. Kouvari M, Panagiotakos DB, Yannakoulia M, Gerogousopoulou E, Critselis E, Chrysohoou C, et al. Transition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular disease incidence: the ATTICA cohort study. Metabolism. 2019;93:18–24.

    Article  PubMed  CAS  Google Scholar 

  37. Hellgren MI, Daka B, Jansson PA, Lindblad U, Larsson CA. Insulin resistance predicts early cardiovascular morbidity in men without diabetes mellitus, with effect modification by physical activity. Eur J Prev Cardiol. 2015;22(7):940–9.

    Article  PubMed  Google Scholar 

  38. Wieberdink RG, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM, Ikram MA. Insulin resistance and the risk of stroke and stroke subtypes in the nondiabetic elderly. Am J Epidemiol. 2012;176(8):699–707.

    Article  PubMed  Google Scholar 

  39. Rundek T, Gardener H, Xu Q, Goldberg RB, Wright CB, Boden-Albala B, et al. Insulin resistance and risk of ischemic stroke among nondiabetic individuals from the northern Manhattan study. Arch Neurol. 2010;67(10):1195–200.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Hedblad B, Nilsson P, Engström G, Berglund G, Janzon L. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med. 2002;19(6):470–5.

    Article  PubMed  CAS  Google Scholar 

  41. Ghoreishian H, Tohidi M, Derakhshan A, Hajsheikkholeslami F, Azizi F, Kazempour-Ardebili S, et al. Presence of hypertension modifies the impact of insulin resistance on incident cardiovascular disease in a Middle Eastern population: the Tehran Lipid and Glucose Study. Diabet Med. 2015;32(10):1311–8.

    Article  PubMed  CAS  Google Scholar 

  42. Nakamura K, Sakurai M, Miura K, Morikawa Y, Ishizaki M, Yoshita K, et al. Homeostasis model assessment of insulin resistance and the risk of cardiovascular events in middle-aged non-diabetic Japanese men. Diabetologia. 2010;53(9):1894–902.

    Article  PubMed  CAS  Google Scholar 

  43. Vulcan A, Manjer J, Ohlsson B. High blood glucose levels are associated with higher risk of colon cancer in men: a cohort study. BMC Cancer. 2017;17(1):842.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Hsu CN, Chang CH, Lin YS, Lin JW, Caffrey JL. Association for serum C-peptide concentrations with cancer mortality risk in pre-diabetes or undiagnosed mortality. PLoS ONE. 2013;8(2):e55625.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Perseghin G, Calori G, Lattuada G, Ragogna F, Dugnani E, Garancini MP, et al. Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol. 2012;49(6):421–8.

    Article  PubMed  CAS  Google Scholar 

  46. Kwanbujan K, Panprathip P, Phosat C, Chumpathat N, Wechjakwen N, Puduang S, et al. Association of retinol binding protein 4 and transthyretin with triglyceride levels and insulin resistance in rural thais with high type 2 diabetes risk. BMC Endocr Disord. 2018;18(1):26.

    Article  Google Scholar 

  47. Tatsumi Y, Morimoto A, Asayama K, Sonoda N, Miyamatsu N, Ohno Y, et al. Fasting blood glucose predicts incidence of hypertension independent of HbA1c levels and insulin resistance in middle-aged Japanese: the Saku study. Am J Hypertens. 2019;32(12):1178–85.

    Article  PubMed  CAS  Google Scholar 

  48. Stamatelopoulos K, Apostolakis M, Augoulea A, Paschou SA, Armeni E, Panoulis K, et al. Predictors of incident hypertension in healthy non-diabetic postmenopausal women with normal renal function. Gynecol Endocrinol. 2019;35(12):1063–6.

    Article  PubMed  CAS  Google Scholar 

  49. Xun P, Liu K, Cao W, Sidney S, Williams OD, He K. Fasting insulin level is positively associated with incidence of hypertension among American young adults: a 20-year follow-up study. Diabetes Care. 2012;35(7):1532–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Castro LL, Brant L, Diniz MFHS, Lotufo P, Bensenor I, Griep, RH, et al. Insulin resistance independently predicts hypertension in individuals with lower education status—from the ELSA-BRASIL Cohort study. JACC. 2021;77(18).

  51. Boyko EJ, Shaw JE, Zimmet PZ, Chitson P, Toumilehto J, Alberti KG. A prospective study of glycemia, body size, insulin resistance and the risk of hypertension in Mauritius. J Hypertens. 2008;26(9):1742–9.

    Article  PubMed  CAS  Google Scholar 

  52. Wang F, Han L, Hu D. Fasting insulin, insulin resistance and risk of hypertension in the general population: a meta-analysis. Clin Chim Acta Int J Clin Chem. 2017;464:57–63.

    Article  CAS  Google Scholar 

  53. Zhang X, Li J, Zheng S, Luo Q, Zhou C, Wang C. Fasting insulin, insulin resistance, and risk of cardiovascular or all-cause mortality in non-diabetic adults: a meta-analysis. Biosci Rep. 2017;37(5).

  54. Saboori S, Rad EY, Birjandi M, Mohiti S, Falahi E. Serum insulin level, HOMA-IR and prostate cancer risk: a systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(1):110–5.

    Article  PubMed  Google Scholar 

  55. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–95.

    Article  PubMed  Google Scholar 

  56. Rodríguez-Gutiérrez R, Salcido-Montenegro A, González-González JG. Early clinical expressions of insulin resistance: the real enemy to look for. Diabetes Ther. 2018;9(1):435–8.

    Article  PubMed  Google Scholar 

  57. Singh B, Saxena A. Surrogate markers of insulin resistance: a review. World J Diabetes. 2010;1(2):36–47.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Pan K, Nelson RA, Wactawski-Wende J, Lee DJ, Manson JE, Aragaki AK, et al. Insulin resistance and cancer-specific and all-cause mortality in postmenopausal women: the women’s health initiative. J Natl Cancer Inst. 2020;112(2):170–8.

    Article  PubMed  Google Scholar 

  59. Zheng S, Xu H, Zhou H, Ren X, Han T, Chen Y, et al. Associations of lipid profiles with insulin resistance and β cell function in adults with normal glucose tolerance and different categories of impaired glucose regulation. PLoS ONE. 2017;12(2): e0172221.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Isokuortti E, Zhou Y, Peltonen M, Bugianesi E, Clement K, Bonnefont-Rousselot D, et al. Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. Diabetologia. 2017;60(10):1873–82.

    Article  PubMed  Google Scholar 

  61. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801.

    Article  PubMed  Google Scholar 

  63. Bjornstad P, Eckel RH. Pathogenesis of lipid disorders in insulin resistance: a brief review. Curr Diab Rep. 2018;18(12):127.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544–60.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Plataforma INVEST-KER Unit Mayo Clinic (KER Unit Mexico), School of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico

    José G. González-González, Miguel Zambrano-Lucio, Erick Burciaga-Jimenez, Patricia L. Castillo-Morales, Mariano Garcia-Campa, Ricardo César Solis, Alejandro D González-Colmenero & René Rodríguez-Gutiérrez

  2. Knowledge and Evaluation Research Unit, Mayo Clinic, 201 W. Center St, Rochester, MN, 55902, USA

    José G. González-González & René Rodríguez-Gutiérrez

  3. Division of Endocrinology, Internal Medicine Department, School of Medicine and University Hospital “Dr. Jose E. Gonzalez”, Universidad Autonoma de Nuevo Leon, Ave. Gonzalitos y Madero s/n 64460, Monterrey, Nuevo León, México

    Jorge R. Violante-Cumpa & René Rodríguez-Gutiérrez

  4. Research Unit, School of Medicine and University Hospital “Dr. Jose E. Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico

    José G. González-González, Jorge R. Violante-Cumpa, Miguel Zambrano-Lucio, Erick Burciaga-Jimenez, Patricia L. Castillo-Morales, Mariano Garcia-Campa, Ricardo César Solis, Alejandro D González-Colmenero & René Rodríguez-Gutiérrez

Authors
  1. José G. González-González
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jorge R. Violante-Cumpa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miguel Zambrano-Lucio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Erick Burciaga-Jimenez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Patricia L. Castillo-Morales
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mariano Garcia-Campa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ricardo César Solis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alejandro D González-Colmenero
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. René Rodríguez-Gutiérrez
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: [José G González-González and René Rodríguez-Gutiérrez] ; methodology [René Rodríguez-Gutiérrez, Alejandro D González-Colmenero and Miguel Zambrano-Lucio]; formal analysis and investigation: [Miguel Zambrano-Lucio, Patricia L Castillo-Morales and Mariano Garcia-Campa]; writing-original draft preparation: [Jorge R Violante-Cumpa, Miguel Zambrano-Lucio and Erick Burciaga-Jimenez]; writing-review and editing: [Erick Burciaga-Jimenez, Jorge R Violante-Cumpa, Patricia L Castillo-Morales and Ricardo César Solis]; funding acquisition: [NA]; resources: [NA]; supervision: [José G González-González and René Rodríguez-Gutiérrez]

Corresponding author

Correspondence to René Rodríguez-Gutiérrez.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose. The authors have no competing interests to declare that are relevant to the content of this article. All authors certify that they have no affiliations with or no involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. The authors have no financial or proprietary interests in any material discussed in this article.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 40 KB)

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

González-González, J.G., Violante-Cumpa, J.R., Zambrano-Lucio, M. et al. HOMA-IR as a predictor of Health Outcomes in Patients with Metabolic Risk Factors: A Systematic Review and Meta-analysis. High Blood Press Cardiovasc Prev 29, 547–564 (2022). https://doi.org/10.1007/s40292-022-00542-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40292-022-00542-5

Keywords

Search

Navigation